A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Experts say a healthy vaginal microbiome may cut down one's risk of infections like HPV in check. Probiotics can balance pH, ...

It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...

Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD ...

Cervical cancer begins in the epithelial cells of the cervix following an ongoing period of infection with high-risk types of ...

Around 11,500 Americans are diagnosed with cervical cancer each year, according to data from the Centers for Disease Control ...

For cervical cancer patients in Saskatchewan, the new Interstitial High-Dose-Rate (HDR) Gynecological Brachytherapy program ...

How common is endometrial cancer? In the United States, cancer of the endometrium (the lining of the uterus) is the most common cancer of the female reproductive organs. The American Cancer Society ...

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...